Sodium Tanshinone II A Sulfonate for Coronary Heart Disease: A Systematic Review of Randomized Controlled Trials
暂无分享,去创建一个
Ke-Ji Chen | Hao Xu | Hao Xu | Ke-Ji Chen | Jingen Li | Mei-Li Yu | Si-Ming Li | Xiang Gao | Jin-Gen Li | Xiang Gao | Meili Yu | Si-ming Li
[1] Jie Ren,et al. Salvia miltiorrhiza in Treating Cardiovascular Diseases: A Review on Its Pharmacological and Clinical Applications , 2019, Front. Pharmacol..
[2] J. Higgins,et al. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .
[3] Hao Xu,et al. Tanshinone IIA: A Promising Natural Cardioprotective Agent , 2012, Evidence-based complementary and alternative medicine : eCAM.
[4] W. Yao,et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. , 2013, Journal of the American College of Cardiology.
[5] J. Rich. Cancer stem cells: master gatekeepers and regulators of cancer growth and metastasis Introduction , 2016, Medicine.
[6] Hao Xu,et al. Anti-Inflammatory and Immunomodulatory Mechanism of Tanshinone IIA for Atherosclerosis , 2014, Evidence-based complementary and alternative medicine : eCAM.
[7] P. Libby,et al. The Present and FutureReview Topic of the WeekInterleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond , 2017 .
[8] Wei Wang,et al. Tanshinone IIA Restores Dynamic Balance of Autophagosome/Autolysosome in Doxorubicin-Induced Cardiotoxicity via Targeting Beclin1/LAMP1 , 2019, Cancers.
[9] Da-zhuo Shi,et al. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. , 2006, Chinese medical journal.
[10] D. Capuzzi,et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. , 2008, The American journal of cardiology.
[11] J. Higgins,et al. Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.
[12] Claudio Napoli,et al. Rethinking primary prevention of atherosclerosis-related diseases. , 2006, Circulation.
[13] Yang Jiao,et al. Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial , 2017, Scientific Reports.
[14] A. Keech,et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.
[15] V. Kadirkamanathan,et al. A Zebrafish Compound Screen Reveals Modulation of Neutrophil Reverse Migration as an Anti-Inflammatory Mechanism , 2014, Science Translational Medicine.
[16] Jie Wang,et al. Bioactive Ingredients in Chinese Herbal Medicines That Target Non-coding RNAs: Promising New Choices for Disease Treatment , 2019, Front. Pharmacol..
[17] Nathan D. Wong,et al. Epidemiological studies of CHD and the evolution of preventive cardiology , 2014, Nature Reviews Cardiology.
[18] P. Libby,et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial , 2017, The Lancet.